COMPOUND PROFILE / PEPTIDES & ANALOGUES
Tesamorelin is a growth hormone-releasing factor analogue with specific US product indications. The EGRIFTA WR label concerns excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight-loss management.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Focused editorial source update: 20 October 2026. Primary records linked; abstract/label scope disclosed. No independent clinical review claimed.
Tesamorelin is a growth hormone-releasing factor analogue with specific US product indications. The EGRIFTA WR label concerns excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight-loss management.
Tesamorelin acts through the growth hormone axis. A physiological effect is not by itself a recommendation: indication, contraindications and monitoring remain part of the product-specific assessment.
For a clinically relevant starting point, read the product’s clinical-studies section and indication together. Do not expand a finding in HIV-associated lipodystrophy into a claim about routine fat loss, sports recovery or an unlabelled research preparation.
Preclinical pharmacology cannot substitute for the labelled human indication. This profile prioritises actual product information and does not use animal findings to broaden the approved use.
The US WR label lists contraindications and monitoring requirements, including active malignancy, pregnancy, IGF-I elevation and glucose intolerance. This short list is not complete. Follow the full prescribing information with a qualified professional.
EGRIFTA WR has a defined US indication and is not indicated for weight-loss management. EGRIFTA WR and EGRIFTA SV have different formulations and instructions; the labels state they are not substitutable. This does not establish approval of every material labelled tesamorelin or approval in every country.
The relevant dose reference is the current label for the exact prescribed product. WR and SV instructions differ; neither should be copied onto an unlabelled research vial. See the original product labels and a prescriber/pharmacist rather than treating this page as dosing instructions.
The supplied Tesamorelin profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Follow the cited records and registered research. Profiles remain research drafts.